Figure EV5. Edaravone treatment ameliorates the Skm mitochondrial dysfunctions (related to Figs 4, 5 and 7).

• A
  NADP/NADPH levels in Skm extracts from wt (n = 8) and Low_OXPHOS (n = 8) animals.
• B
  HFD/chow and Low_OXPHOS/wt iTRAQ ratios of Skm proteins from OXPHOS system (wt, n = 10–12; Low_OXPHOS, n = 10–12). Higher intensities of red or blue color represent higher or lower expression ratios, respectively. HFD induced the downregulation of the majority of OXPHOS complex subunits.
• C
  Representative WB of Skm OXPHOS system proteins in mice fed with chow or HFD. Two samples per condition are shown. Each sample contains extracts from 3 mice. NDUFA9 (CI), SDHA and B (CII), ETF subunits (A) and (B), ETFDH, CoreII (CIII), subunit 1 (CIV), βF1(CV), and hATPIF1 immunoblots are shown. Tubulin is provided as a loading control. Histograms show the quantification of specific protein expression (wt, n = 6; Low_OXPHOS, n = 6; wt + HFD, n = 6; Low_OXPHOS + HFD, n = 6).
• D
  Enzymatic activity of respiratory complex CI in Skm isolated mitochondria from wt and Low_OXPHOS mice fed with chow or HFD (wt, n = 4; Low_OXPHOS, n = 4; wt + HFD, n = 4; Low_OXPHOS + HFD, n = 4).
• E
  Representative images of hindlimb muscles of mice treated with edaravone (wt + edaravone, n = 4; Low_OXPHOS + edaravone, n = 4).
• F
  Plasma BCAA levels in wt and Low_OXPHOS mice treated or not with edaravone (wt, n = 4; Low_OXPHOS, n = 4; wt + edaravone, n = 4; Low_OXPHOS + edaravone, n = 4).
• G
  14C(u)‐leucine uptake in myocytes expressing ATPIF1_H49K treated or not with edaravone. Data are the mean ± SEM of n = 3 experiments, 6 replicas/condition.
• H
  Food intake (g HFD/mouse/day) in wt and LowOXPHOS animals treated or not with edaravone (wt, n = 5; wt + edaravone, n = 5). No differences were observed.

Data information: Data are the mean ± SEM of indicated (n) mice. *P < 0.05 when compared to wt; ^# P < 0.05 when compared to ATPIF1_H49K by ANOVA and Student's t‐test.Source data are available online for this figure.